Listen to this podcast for thought-provoking discussions on the global obesity epidemic and the role of pharmaceutical drugs in addressing it. With over a billion people worldwide considered obese, the demand for treatments has never been higher. Companies like Novo Nordisk and Eli Lilly have experienced a surge in market value thanks to their innovative weight-loss medications.
Join hosts Alice Fulwood, Mike Bird, and Tom Lee-Devlin as they explore how these drugs are not only benefiting drug companies financially but also reshaping the economy. Guests including The Economist’s Georgia Banjo, pharmaceuticals analyst Michael Nedelcovych, and John Cawley, a professor at Cornell University, offer expert insights on the topic.
The Economist Podcast covers a range of topics from global politics and business to science and technology. Subscribe now to stay informed and up-to-date on what matters most in the world. To learn more about Economist Podcasts+, visit our FAQs page or watch a video on how to link your account.
If you’re interested in accessing podcast transcripts, simply reach out to [email protected] The Economist is committed to improving accessibility and is exploring new ways to expand our podcast-transcript offering. Tune into the podcast on Apple Podcasts or Spotify to stay ahead of the curve on the latest global trends and discussions.
In this episode of The Economist Podcast, we dive deep into one of the biggest health issues facing our world today: obesity. With over 1 billion people worldwide classified as obese, it’s clear that there is an urgent need for solutions that can help people manage their weight effectively.
We invited experts from various fields – including pharmaceuticals analyst Michael Nedelcovych, professor John Cawley at Cornell University, and Georgia Banjo from The Economist – to share their insights on how pharmaceutical drugs can play a role in addressing this growing problem.
One company that has been making waves in this space is Novo Nordisk – whose innovative weight loss medications have seen significant success in recent years.
Our hosts discussed how these drugs not only benefit drug companies financially but also reshape economies around the world.
Of course, there are concerns about safety when it comes to any kind of medication – especially those designed for weight loss purposes.
But if used responsibly under medical supervision, these drugs could represent an important tool in helping individuals overcome obesity.
As always with The Economist Podcast, we delved into all aspects of this issue – from its causes and consequences to potential solutions moving forward.
If you’re interested in learning more about this topic or want access to exclusive content related to other hot topics in healthcare and beyond, be sure to subscribe now!
